Xiaoquan Wang

Dr. Xiaoquan Wang

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXiaoquan Wang
Xiaoquan Wang
YWYouqiao Wang
Youqiao Wang
ACAnqi Cao
Anqi Cao
QLQinhong Luo
Qinhong Luo
DCDaoyuan Chen
Daoyuan Chen
JQJunmin Quan
Junmin Quan
Cyclic GMP-AMP synthase (cGAS) is an essential sensor of aberrant cytosolic DNA for initiating innate immunity upon invading pathogens and cellular stress, which is considered as a potential drug target for autoimmune and autoinflammatory diseases. Here, we report the discovery of a class of cyclopeptide inhibitors of cGAS identified by an in vitro screening assay from a focused library of cyclic peptides. These cyclopeptides specifically bind to the DNA binding site of cGAS and block the binding of dsDNA with cGAS, subsequently inhibit dsDNA-induced liquid phase condensation and activation of cGAS. The specificity and potency of one optimal lead XQ2B were characterized in cellular assays. Concordantly, XQ2B inhibited herpes simplex virus-1 (HSV-1)-induced antiviral immune responses and enhanced HSV-1 infection in vitro and in vivo. Furthermore, XQ2B significantly suppressed the elevated levels of type I interferon and proinflammatory cytokines in primary macrophages from Trex1-/- mice and systemic inflammation in Trex1-/- mice. XQ2B represents the specific cGAS inhibitor targeting protein-DNA interaction and phase separation and serves as a scaffold for the development of therapies in the treatment of cGAS-dependent inflammatory diseases.

10 August 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
GLGuomin Li
Guomin Li
JZJie Zhao
Jie Zhao
BLBing Li
Bing Li
JMJianxiong Ma
Jianxiong Ma
QZQiubo Zhao
Qiubo Zhao
JLJun Liu
Jun Liu

31 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
ACAnqi Cao
Anqi Cao
煜李煜荣 李
煜荣 李
YFYanqiao Feng
Yanqiao Feng
XWXiaoquan Wang
Xiaoquan Wang
WWWenyu Wei
Wenyu Wei
JQJunmin Quan
Junmin Quan
Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation of keratinocytes and infiltration of inflammatory cells. Significant challenges remain in developing effective and safe targeted therapies for psoriasis. Here, we reported the discovery of novel cystamine derivatives for the treatment of psoriasis. These compounds effectively attenuated LPS-induced inflammation in vitro, and the optimal candidate CS1 ameliorated imiquimod-induced psoriasis-like inflammation in mice. Mechanistically, CS1 bound and inhibited the deacetylase HDAC6, subsequently inhibited the AKT, MAPK, and STAT3 pathways, attenuated the hyperproliferation and altered differentiation of keratinocytes and reduced the infiltration of immune cells. These findings suggest that HDAC6 may serve as a potential target for drug development in the treatment of psoriasis.

1 September 2011 in Avian Diseases Digest
Verified
Journal Article
Closed access
ZHZenglei Hu
Zenglei Hu
SHShunlin Hu
Shunlin Hu
CMChun Meng
Chun Meng
XWXiaoquan Wang
Xiaoquan Wang
JZJie Zhu
Jie Zhu
XLXiufan Liu
Xiufan Liu

7 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
WZWenlv Zheng
Wenlv Zheng
WTWei Tang
Wei Tang
JWJianzheng Wang
Jianzheng Wang
煜李煜荣 李
煜荣 李
SWShengnan Wang
Shengnan Wang
JQJunmin Quan
Junmin Quan
Background /Objectives: Cyclic dinucleotide stimulator of interferon genes (STING) agonists have emerged as potential agents in cancer immunotherapy, but their clinical applications are limited by relatively poor pharmacokinetic properties. Methods: A luciferase reporter assay was employed to screen delivery peptides capable of promoting cellular activating effect of cyclic dinucleotide STING agonists. The potent candidates were further confirmed by enzyme-linked immunosorbent assay (ELISA), real-time quantitative PCR (qPCR) and Western blotting analysis. Colon and melanoma cancer mouse models were used to examine the antitumor efficacy of the delivery peptides with cyclic GMP–AMP (cGAMP) as a therapeutic agents or vaccine adjuvant. Results: We identify a class of STING agonist delivery peptides that efficiently facilitate cytosolic delivery of cyclic dinucleotide STING agonists and promote STING activation by forming peptide coacervates. Intratumoral administration of Sti3-4A and cGAMP effectively suppressed tumor growth and promoted antitumor immune response. Furthermore, the conjugation of tumor-specific antigen peptides with Sti3-4A promoted cytosolic co-delivery of antigen peptides and cGAMP, thus significantly boosting APC maturation, antigen cross-presentation, and T cell responses to peptide antigens. Prophylactic and therapeutic immunization with the conjugated peptides and cGAMP inhibited tumor growth in multiple murine tumor models. Conclusion: These findings establish STING agonist delivery peptides as a versatile platform for cancer immunotherapy.